Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Theralase current status

<< Previous

Bullboard Posts

Next >>

Comment by StevenBirchon Jun 17, 2021 8:09am

189 Views

Post# 33400772

RE:RE:RE:RE:Theralase current status

My guess is once they make their NMIBC submission to the FDA we could get news on that. They did say when Phase II was 'well underway' so I think that would qualify.

Yajne wrote: Also great to see that under ACT tab they are describing both GBM and NSCLC as "late preclinical". Expect that further details shared about status of these at the upcoming AGM. What does "late preclinical" really mean in terms of timing to kick off Ph1b trials?

<< Previous

Bullboard Posts

Next >>

These cold weather stocks are looking to heat up for winter